Abbott Laboratories (NYSE:ABT) Given New $136.00 Price Target at Citigroup

Abbott Laboratories (NYSE:ABT) had its price objective reduced by Citigroup from $140.00 to $136.00 in a research note released on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the healthcare product maker’s stock.

Other analysts have also issued research reports about the stock. Piper Sandler cut their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Royal Bank Of Canada lowered their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Evercore cut their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, Daiwa Securities Group dropped their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Price Performance

NYSE:ABT opened at $110.20 on Wednesday. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The firm’s 50-day simple moving average is $115.25 and its 200 day simple moving average is $124.19. The firm has a market cap of $191.50 billion, a price-to-earnings ratio of 29.62, a P/E/G ratio of 1.76 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the firm earned $1.34 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. Company insiders own 0.46% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. State Street Corp raised its position in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares during the period. Capital International Investors lifted its stake in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after buying an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP boosted its holdings in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors boosted its holdings in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares during the period. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott launched year two of the “Abbott Dream Team” program with Real Madrid to engage U.S. youth and raise brand visibility for Abbott’s consumer/diagnostics businesses — a marketing move that can boost long‑term consumer awareness. Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team’
• Positive Sentiment: Coverage highlighting Abbott as a durable dividend name / “safer” dividend aristocrat supports income‑oriented investor demand and may underpin share support despite near‑term volatility. Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats
• Positive Sentiment: Analyst writeups from Zacks highlight Abbott as both a long‑term value and growth stock based on style scores — these pieces can attract buy‑and‑hold investors and lift sentiment over time. Why Abbott (ABT) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Recent short‑term price coverage noted a bounce to roughly $112.65 on the last close, reflecting intra‑week volatility; this is informational but not a catalyst on its own. Abbott (ABT) Rises Higher Than Market: Key Facts
• Negative Sentiment: Citigroup trimmed its price target from $140 to $136 while maintaining a “buy” rating — a downgrade in upside potential that can blunt investor enthusiasm and weigh on the share price. Citigroup trims ABT price target (Benzinga)
• Negative Sentiment: Valuation and performance writeups point to a mixed share performance (YTD and 1‑year declines) and debate whether current pricing fully discounts Abbott’s growth risks — such narratives can trigger additional selling from momentum or quant strategies. Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.